Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45+
SponsorLinkoeping University
About this trial
The goal of this randomised controlled trial is to investigate the effects of and compare two modes of physical exercise (strength training and high-intensity aerobic exercise) to unchanged physical activity on vasomotor symptoms (hot flushes) in postmenopausal women. The main question it aims to answer is the effect of 15 weeks of strength training vs high intensity aerobic training vs unchanged physical activity on frequency and severity of hot flushes. Participants will be randomised to:
1. strength training 2. high-intensity aerobic training 3. untreated control group.
Researchers will compare strength training, high-intensity aerobic training and untreated control group to see if training can reduce hot flushes.
Eligibility criteria
Qualifiers
Postmenopausal women (one of: ≥ 12 months since last menstruation; amenorrhea due to intrauterine device or hysterectomy and Follicle Stimulating Hormone (FSH) >30 mIU/ml; bilateral oophorectomy; induced menopause due to chemotherapy or radiation and ≥2 years amenorrhea);
≥ 28 moderate to severe hot flushes per week during a 2-week screening period, registered through a daily VMS diary;
Age ≥45 years;
Physical ability to participate in strength training or high intensity aerobic exercise for 60 minutes, 3 times/week during 15 weeks;
Disqualifiers
Regular physical activity >30 minutes per week of vigorous intensity or ≥150 minutes of moderate intensity or combined activities representing maximum 150 minutes of moderate intensity;
Use of systemic menopausal hormone therapy the last 2 months;
Use of natural preparations such as herbal preparations for VMS, or other medications for VMS the last 2 months;
Capillary hemoglobin <110 g/l;
Trial design
Treatments tested in this trial
- Strength training
- High-intensity aerobic training
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Linkoeping University
Lead sponsor
Region Östergötland
Collaborator
Länssjukhuset i Kalmar län
Collaborator
Source ClinicalTrials.gov